Higgins, Peter

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial

Hueber, W., Sands, B. E., Lewitzky, S., Vandemeulebroecke, M., Reinisch, W., Higgins, P. D. R., Wehkamp, J., Feagan, B. G., Yao, M. D., Karczewski, M., et al. (2012) · Gut

Inflammatory Bowel DiseasePsoriasis: Treatment and Pathogenesis

Cited by 1,547

A Primer on Effectiveness and Efficacy Trials

Singal, A. G., Higgins, P. D. R., & Waljee, A. K. (2014) · Clinical and Translational Gastroenterology

Statistical Methods in Clinical TrialsAdvanced Causal Inference Techniques

Cited by 698

Colorectal Cancer in Inflammatory Bowel Disease

Higgins, P., & Stidham, R. (2018) · Clinics in Colon and Rectal Surgery

Inflammatory Bowel DiseaseColorectal Cancer Screening and Detection

Cited by 295

Performance of a deep learning model vs human reviewers in grading endoscopic disease severity of patients with ulcerative colitis

Stidham, R. W., Liu, W., Bishu, S., Rice, M. D., Higgins, P. D. R., Zhu, J., Nallamothu, B. K., & Waljee, A. K. (2019) · JAMA Network Open

Inflammatory Bowel DiseaseAI in cancer detection

Cited by 285

Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn’s Disease: A Phase 2a Study

Sands, B. E., Chen, J., Feagan, B. G., Penney, M., Rees, W. A., Danese, S., Higgins, P. D. R., Newbold, P., Faggioni, R., Patra, K., et al. (2017) · Gastroenterology

Inflammatory Bowel DiseasePsoriasis: Treatment and Pathogenesis

Cited by 279

Primary sclerosing cholangitis: meta-analysis of diagnostic performance of MR cholangiopancreatography

Dave, M., Elmunzer, B. J., Dwamena, B. A., & Higgins, P. D. R. (2010) · Radiology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 265

Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis

Higgins, P. D. R., Schwartz, M., Mapili, J., Krokos, I., Leung, J., & Zimmermann, E. M. (2005) · Gut

Inflammatory Bowel DiseaseOcular Diseases and Behçet’s Syndrome

Cited by 244

Novel Fecal Biomarkers That Precede Clinical Diagnosis of Ulcerative Colitis

Galipeau, H. J., Caminero, A., Turpin, W., Bermudez-Brito, M., Santiago, A., Libertucci, J., Constante, M., Raygoza Garay, J. A., Rueda, G., Armstrong, S., et al. (2021) · Gastroenterology

Gut microbiota and healthInflammatory Bowel Disease

Cited by 190

Xanthine Oxidase Inhibition For The Treatment Of Cardiovascular Disease: A Systematic Review and Meta‐Analysis

Higgins, P., Dawson, J., Lees, K. R., McArthur, K., Quinn, T. J., & Walters, M. R. (2012) · Cardiovascular Therapeutics

Gout, Hyperuricemia, Uric AcidCardiovascular Health and Disease Prevention

Cited by 164

Allopurinol and Cardiovascular Outcomes in Adults With Hypertension

MacIsaac, R. L., Salatzki, J., Higgins, P., Walters, M. R., Padmanabhan, S., Dominiczak, A. F., Touyz, R. M., & Dawson, J. (2016) · Hypertension

Gout, Hyperuricemia, Uric AcidBlood Pressure and Hypertension Studies

Cited by 124

Flagellin-mediated activation of IL-33-ST2 signaling by a pathobiont promotes intestinal fibrosis

Imai, J., Kitamoto, S., Sugihara, K., Nagao-Kitamoto, H., Hayashi, A., Morhardt, T. L., Kuffa, P., Higgins, P. D. R., Barnich, N., & Kamada, N. (2019) · Mucosal Immunology

Inflammatory Bowel DiseaseIL-33, ST2, and ILC Pathways

Cited by 91

Su1930 – Safety and Efficacy of Olorinab, a Peripherally Restricted, Highly Selective, Cannabinoid Receptor 2 Agonist in a Phase 2A Study in Chronic Abdominal Pain Associated with Crohn’s Disease

Yacyshyn, B., Ginsberg, D. C., Gilder, K., Walsh, B., English, B., Turner, S. A., Klassen, P., Hanauer, S. B., Barish, C. F., & Higgins, P. D. (2019) · Gastroenterology

Cannabis and Cannabinoid ResearchInflammatory Bowel Disease

Cited by 17

Response to Büning et al.

Adler, J., & Higgins, P. D. R. (2011) · American Journal of Gastroenterology

Gastrointestinal disorders and treatmentsInflammatory Bowel Disease

Cited by 0